Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity.
Total raised: $62M
Founded date: 2015
Investors 6
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Vida Ventu... | vidaventur... |
| - | Mission Bi... | missionbio... |
| - | Sofinnova ... | sofinnova.... |
| - | MBC BioLab... | mbcbiolabs... |
| - | SV Health ... | svhealthin... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.01.2018 | Series B | $62M | New Enterp... |
Mentions in press and media 16
| Date | Title | Description | Source |
| 30.03.2021 | Pionyr Immunotherapeutics Collaborates with Lonza to Support... | Quote from Henit Lapid, Head Mammalian Commercial Development and Marketing, Lonza: “The collaborat... | svhealthin... |
| 23.06.2020 | Gilead to buy 49.9% stake in biotech startup Pionyr Immunoth... | Gilead Sciences announced Tuesday it would buy a 49.9% stake in biotech startup Pionyr Immunotherape... | techstartu... |
| 23.06.2020 | Gilead buys nearly 50% equity interest in cancer immunothera... | Pionyr’s last major financing was in December 2017, when it closed a $62 million Series B financing ... | medcitynew... |
| 23.06.2020 | Gilead Sciences To Acquire 49.9 % Equity In Pionyr Immunothe... | Gilead Sciences, Inc. (Nasdaq: GILD) will acquire a 49.9 % equity interest in Pionyr Immunotherapeut... | finsmes.co... |
| 10.01.2018 | Pionyr Immunotherapeutics Completes $62M Series B Financing | - | mbcbiolabs... |
| 14.12.2017 | Pionyr Immunotherapeutics Inks $62M Series B | SAN FRANCISCO, CA, Pionyr Immunotherapeutics announced the closing of a $62 million Series B inves... | vcnewsdail... |
| 14.12.2017 | Term Sheet — Friday, December 14 | WHO BELONGS ON THE MT. RUSHMORE OF VCS? Good morning Term Sheet readers, this is Jeff John Roberts ... | fortune.co... |
| 13.12.2017 | NEA Leads $62M Series B for Pionyr Immunotherapeutics | Pionyr Immunotherapeutics, Inc., a company developing antibody therapeutics that increase the body's... | citybizlis... |
| 13.12.2017 | Pionyr Immunotherapeutics Completes $62 Million Series B Fin... | - | svhealthin... |
| 13.12.2017 | Pionyr Immunotherapeutics gains meaty $62M series B | California startup Pionyr is using $62 million of VC-backed funding to target antibodies in the tumo... | fiercebiot... |
Show more